Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin

Journal of Clinical Oncology

Volumn 18, Issue 4, 2000, Pages 904-914

  Baselga, Jose ^a   Pfister, D ^a   Cooper, M R ^a   Cohen, R ^a   Burtness, B ^a   Bos, M ^a   D'Andrea, G ^a   Seidman, A ^a   Norton, L ^a   Gunnett, K ^a   Falcey, J ^a   Anderson, V ^a   Waksal, H ^a   Mendelsohn, J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIBODY; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY;

ARTICLE; ASTHENIA; CLINICAL TRIAL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EPIGLOTTITIS; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN ALLERGY;

EID: 19244366949     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.4.904     Document Type: Article

References (41)

1. Aaronson SA: Growth factors and cancer. Science 254:1146-1153, 1991
2. Carpenter G: Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem 56:881-914, 1987
3. Carpenter G, Cohen S: Epidermal growth factor. J Biol Chem 265:7709-7712, 1990
4. Di Marco E, Pierce JG, Fleming TP, et al: Autocrine interaction between TGF alpha and the EGF-receptor: Quantitative requirements for induction of the malignant phenotype. Oncogene 4:831-838, 1989
5. Derynck R: The physiology of transforming growth factor-alpha. Adv Cancer Res 58:27-52, 1992
6. Sporn MB, Todaro GJ: Autocrine growth factors and cancer. Nature 313:747-751, 1985
7. Salomon DS, Brandt R, Ciardiello F, et al: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232, 1995
8. Modjtahedi H, Eccles S, Box G, et al: Immunotherapy of human tumor xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction. Br J Cancer 67:254-261, 1993
9. Masui H, Kawamoto T, Sato JD, et al: Inhibition of human tumor cells in athymic mice by anti-EGF receptor monoclonal antibodies. Cancer Res 44:1002-1007, 1984
10. Rodeck U, Herlyn M, Herlyn D, et al: Efficacy of antibodies to epidermal growth factor receptor: Immunologically mediated and effector cell-independent effects. Cancer Res 47:3692-3696, 1987
11. Aboud-Pirak E, Hurwitz E, Pirak ME, et al: Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 80:1605-1611, 1988
12. Pellegrini R, Centis F, Martignone S, et al: Characterization of a monoclonal antibody directed against the epidermal growth factor receptor binding site. Cancer Immunol Immunother 34:37-42, 1991
13. Kawamoto T, Sato JD, Le A, et al: Growth stimulation of A431 cells by EGF: Identification of high affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci U S A 80:1337-1341, 1983
14. Gill GN, Kawamoto T, Cochet C, et al: Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 259: 7755-7760, 1984
15. Sato JD, Kawamoto T, Le AD, et al: Biological effect in vitro of monoclonal antibodies to human EGF receptors. Mol Biol Med 1:511-529, 1983
16. Fan Z, Lu Y, Wu X, et al: Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 269:27595-27602, 1994
17. Mendelsohn J, Baselga J: Antibodies to growth factors and receptors, in DeVita VT, Hellman S, Rosenberg SA (eds): Biologic Therapy of Cancer (ed 2). Philadelphia, PA, JB Lippincott, 1995, pp 607-624
18. Wu X, Rubin M, Fan Z, et al: Involvement of p27kip1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 12:1397-1403, 1996
19. Peng D, Fan Z, Lu Y, et al: Anti-epidermal growth factor receptor monoclonal antibody C225 upregulates p27kip1 and induces g1 arrest in prostatic cancer cell line DU145. Cancer Res 56:366-3669, 1996
20. Fan Z, Shang BY, Lu Y, et al: Reciprocal changes in p27kip1 and p21cip1 in growth inhibition mediated by blockade or overexpression of epidermal growth factor receptors. Clin Cancer Res 3:1943-1948, 1997
21. Fan Z, Baselga J, Masui H, et al: Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cisdiamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 53:4637-4642, 1993
22. Baselga J, Norton L, Masui H, et al: Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 85:1327-1333, 1993
23. Baselga J, Norton L, Coplan K, et al: Antitumor activity of paclitaxel in combination with anti-growth factor receptor monoclonal antibodies in breast cancer xenografts. Proc Am Assoc Cancer Res 35:2262, 1994 (abstr)
24. Divgi C, Welt C, Kris M, et al: Phase I and imaging trial of indium-111 labeled anti-EGF receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 83:97-104, 1991
25. Goldstein NI, Prewett M, Zuklys K, et al: Biological efficacy of a chimeric antibody to the epidermal growth factor in a human tumor xenograft model. Clin Cancer Res 1:1311-1418, 1995
26. Rusch V, Baselga J, Cordon-Cardo C, et al: Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 53:2379-2385, 1993
27. Cohen DW, Simak R, Fair WR, et al: Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostate tissues. J Urol 152:2120-2124, 1994
28. Khazaeli MB: Quantitation of mouse monoclonal antibody and human anti-mouse antibody response in serum of patients. Hybridoma 8:231-239, 1989
29. Khazaeli MB, Rogers KJ, LoBuglio AF: Quantitative assay of a human monoclonal IgM antibody (HA-1A) in human serum. J Immunol Methods 117:175-180, 1989
30. Fan Z, Masui H, Altas I, et al: Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 53:4322-4328, 1993
31. Baselga J, Cañadas MA, Codony J, et al: Activated epidermal growth factor receptor: Studies in head and neck tumors and tumor cell lines after exposure to ligand and receptor tyrosine-kinase inhibitors. Proc Am Soc Clin Oncol 18:619a, 1999 (abstr 2392)
32. Mendelsohn J, Shin DM, Donato N, et al: A phase I study of chimerized anti-epidermal growth factor receptor (EGFr) monoclonal antibody, C225, in combination with cisplatin (CDDP) in patients (PTS) with recurrent head and neck squamous cell carcinoma (SCC). Proc Am Soc Clin Oncol 18:389a, 1999 (abstr 1502)
33. Perez-Soler R, Donato NJ, Shin DM, et al: Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852. J Clin Oncol 12:730-739, 1994 (published erratum appears in J Clin Oncol 12:1526, 1994)
34. Petit AM, Rak J, Hung MC, et al: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151:1523-1530, 1997
35. Perrotte P, Matsumoto T, Inoue K, et al: Chimeric monoclonal antibody (Mab) C225 to the epidermal growth factor receptor (EGF-R) antibody inhibits angiogenesis in human transitional cell carcinoma (TCC). Proc Am Assoc Cancer Res 39:316, 1998 (abstr)
36. Mendelsohn J: Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 3:2703-2707, 1997
37. Baselga J, Tripathy D, Mendelsohn J, et al: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996
38. Pegram MD, Lipton A, Hayes DF, et al: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671, 1998
39. Slamon D, Leyland-Jones B, Shak S, et al: Addition of Herceptin[tm] (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized, multinational, controlled phase III trial. Proc Am Soc Clin Oncol 17:377, 1998 (abstr)
40. Pietras RJ, Fendly BM, Chazin VR, et al: Antibody to HER-2/ neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogcne 9:1829-1838, 1994
41. Arteaga CL, Winnier AR, Poirier MC, et al: p185c-erbB-2 signaling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: Association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res 54:3758-3765, 1994